Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.
about
Next-generation antimicrobials: from chemical biology to first-in-class drugsMass spectrometry imaging identifies palmitoylcarnitine as an immunological mediator during Salmonella Typhimurium infection.Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf?Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.Marine Algae as Source of Novel Antileishmanial Drugs: A Review.
P2860
Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Development of an ex vivo lymp ...... tive against Leishmania major.
@en
Development of an ex vivo lymp ...... tive against Leishmania major.
@nl
type
label
Development of an ex vivo lymp ...... tive against Leishmania major.
@en
Development of an ex vivo lymp ...... tive against Leishmania major.
@nl
prefLabel
Development of an ex vivo lymp ...... tive against Leishmania major.
@en
Development of an ex vivo lymp ...... tive against Leishmania major.
@nl
P2093
P2860
P356
P1476
Development of an ex vivo lymp ...... tive against Leishmania major.
@en
P2093
Bruno L Travi
Doug E Frantz
Peter C Melby
Yaneth Osorio
P2860
P356
10.1128/AAC.00887-13
P407
P577
2013-10-14T00:00:00Z